SCYNEXIS Yönetim

Yönetim kriter kontrolleri 2/4

SCYNEXIS CEO'su David Angulo, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 1.21M olup, şirket hissesi ve opsiyonları dahil olmak üzere 46.5% maaş ve 53.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.38% ine doğrudan sahiptir ve bu hisseler $ 171.33K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 9.5 yıldır.

Anahtar bilgiler

David Angulo

İcra Kurulu Başkanı

US$1.2m

Toplam tazminat

CEO maaş yüzdesi46.5%
CEO görev süresi1.8yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi2.1yrs
Yönetim Kurulu ortalama görev süresi9.5yrs

Son yönetim güncellemeleri

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

CEO Tazminat Analizi

David Angulo'un ücretlendirmesi SCYNEXIS'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

US$101m

Dec 31 2023US$1mUS$565k

US$67m

Sep 30 2023n/an/a

US$72m

Jun 30 2023n/an/a

US$44m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$1mUS$482k

-US$63m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$987kUS$461k

-US$33m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$45m

Mar 31 2021n/an/a

-US$53m

Dec 31 2020US$939kUS$447k

-US$55m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$38m

Dec 31 2019US$1mUS$437k

-US$54m

Sep 30 2019n/an/a

-US$37m

Jun 30 2019n/an/a

-US$29m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$769kUS$424k

-US$12m

Sep 30 2018n/an/a

-US$22m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$24m

Dec 31 2017US$768kUS$412k

-US$25m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 1.21M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 650.80K ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

David Angulo (59 yo)

1.8yrs

Görev süresi

US$1,214,710

Tazminat

Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Angulo
CEO, President & Director1.8yrsUS$1.21m0.38%
$ 171.3k
Ivor Macleod
Chief Financial Officer2.1yrsUS$626.90k0.028%
$ 12.5k
Scott Sukenick
Chief Legal Officer & Corporate Secretary7yrsUS$936.70k0.21%
$ 95.0k
Daniella Gigante
Vice President of Human Resources & Information Technologyno dataVeri yokVeri yok

2.1yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: SCYX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Angulo
CEO, President & Director1.8yrsUS$1.21m0.38%
$ 171.3k
Armando Anido
Independent Director5.8yrsUS$98.75k0.066%
$ 29.8k
David Hastings
Independent Director9.2yrsUS$104.25k0.061%
$ 27.6k
Ann Hanham
Independent Director15.9yrsUS$105.25k0.062%
$ 28.1k
Guy MacDonald
Independent Chairman of the Board10yrsUS$128.75k0.084%
$ 38.1k
Steven Gilman
Independent Director9.8yrsUS$106.25k0.063%
$ 28.6k
David Denning
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Peter Pappas
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Oliver Cornely
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Barbara Alexander
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Mahmoud Ghannoum
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Paul Nyirjesy
Member of Scientific Advisory Boardno dataVeri yokVeri yok

9.5yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SCYX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.5 yıldır).